Edwards Lifesciences Corporation (EW) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A reveal several positive factors: raised sales and EPS guidance, strong TAVR performance, and positive European guideline changes. Despite increased SG&A spending, management expects it to normalize, and the company is optimistic about future growth. The raised guidance and strong performance in key areas suggest a positive stock price movement.
Key Financial Performance
Total Sales (Q4 2025) $1.57 billion, grew 11.6% year-over-year. Growth attributed to strength across all product groups.
TAVR Global Sales (Q4 2025) $1.16 billion, increased 10.6% year-over-year. Growth driven by elevated focus on SAPIEN therapy and proactive disease management of severe aortic stenosis patients.
TMTT Global Sales (Q4 2025) $156 million, grew over 40% year-over-year. Growth fueled by global adoption of PASCAL and EVOQUE therapies.
Surgical Product Group Sales (Q4 2025) $254 million, increased 2% year-over-year. Growth impacted by end-of-year distributor inventory adjustments in one country.
Full Year 2025 Total Sales Grew 10.7% year-over-year. Growth attributed to a differentiated strategy and strong execution by experienced teams.
Full Year 2025 TMTT Sales Exceeded $0.5 billion. Growth driven by adoption of PASCAL and EVOQUE therapies.
Adjusted Gross Profit Margin (Q4 2025) 78.3%, compared to 79.0% in the same period last year. Decrease due to additional manufacturing expenses related to new therapies.
Adjusted Operating Profit Margin (Q4 2025) 23.7%, aligned with previous guidance. Full year 2025 adjusted operating profit margin was 27%.
Adjusted EPS (Q4 2025) $0.58, lower than expected due to higher spending on patient access initiatives and a higher-than-expected tax rate.
R&D Expense (Q4 2025) $268 million, 17.1% of sales, compared to 19.6% in the same period last year. Decrease reflects strategic prioritization of investments in structural heart portfolio.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
SAPIEN M3: Launched in the U.S. as the first transcatheter replacement option for mitral disease. Strategic introduction leveraging proven high-value support model.
Next-gen PASCAL: Set to launch in Q4, offering enhanced therapy for edge-to-edge repair for mitral and tricuspid patients.
EVOQUE: Scaling globally, focusing on excellent patient outcomes.
TAVR Expansion: Renewed focus on SAPIEN platform globally, supported by long-term durability data and guideline changes in Europe.
TMTT Growth: Driven by comprehensive portfolio and new product launches, aiming for $2 billion revenue by 2030.
Operational Margin Expansion: Achieved 27% adjusted operating profit margin in 2025, with plans for 150 basis points expansion in 2026.
SG&A Investments: Increased spending on patient access initiatives, including early TAVR education and AHA heart valve initiative.
Structural Heart Focus: Continued focus on structural heart therapies, including new innovations for aortic regurgitation and structural heart failure.
Clinical Evidence Generation: Investing in world-class clinical evidence to differentiate Edwards' valve technologies.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Litigation Risks: The company faced one-time charges related to the JenaValve acquisition that did not close, as well as litigation expenses. Additionally, the reconsideration of the National Coverage Determination (NCD) for TAVR by CMS introduces regulatory uncertainty.
Taxation and Financial Risks: The company experienced a higher-than-expected tax rate in Q4, driven by Pillar Two impact and country income mix, which could affect future profitability.
Supply Chain and Manufacturing Costs: Additional manufacturing expenses related to the fast expansion of new therapies impacted the gross profit margin, which decreased to 78.3% from 79.0% in the prior year.
Market Competition and Share: While the company noted stable competitive positioning globally, the exit of a competitor in Europe highlights potential market volatility. Additionally, the company’s reliance on the SAPIEN platform for growth could be challenged by emerging competitors or alternative technologies.
Strategic Execution Risks: The company’s ambitious growth targets, including achieving $2 billion in TMTT revenue by 2030 and expanding into new therapeutic areas like structural heart failure and aortic regurgitation, require flawless execution. Delays or missteps in these initiatives could impact long-term growth.
Economic and Currency Risks: Foreign exchange rates increased reported sales growth by 170 basis points in Q4, but currency fluctuations remain a risk to financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Sales Growth Guidance for 2026: The company expects an 8% to 10% sales growth rate for 2026, with increased confidence in achieving this target.
Earnings Per Share (EPS) Guidance for 2026: The company projects EPS in the range of $2.90 to $3.05 for 2026, with mid-teens growth expected in Q1.
TAVR Segment Outlook: The company anticipates continued momentum in the TAVR segment, driven by clinical evidence, innovation, and patient access strategies. Potential catalysts include updated national coverage determination for TAVR and guideline evolution in the U.S. and Japan.
TMTT Segment Growth: The TMTT segment is expected to achieve $2 billion in revenue by 2030, with significant growth opportunities starting in 2026. This will be driven by the scaling of EVOQUE, the launch of SAPIEN M3, and the introduction of next-gen PASCAL.
Surgical Product Group Growth: Mid-single-digit sales growth is expected in 2026, supported by the adoption of RESILIA therapies and new innovations like the surgical LAAC technology.
Long-Term Growth Expectations: The company expects average annual sales growth of 10% in 2027 and beyond, with constant currency operating margin expansion.
Structural Heart Expansion: Plans to extend into structural heart failure and aortic regurgitation to create additional growth opportunities and maintain leadership in structural heart therapies.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Authorization: Edwards currently has approximately $2 billion remaining under its share repurchase authorization.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is driving the strong growth in TAVR, and are there any regional differences?
A:The growth in TAVR, which is 10.6% year-over-year, is attributed to compelling evidence from studies like EARLY TAVR, PARTNER III (7 years), and PARTNER II (10 years). These studies have increased physician confidence and focus on TAVR, particularly the SAPIEN platform. Regional differences include share gains from Boston Scientific's exit, particularly in Europe, and strong adoption of the S3UR platform.
Q:What caused the increased SG&A spending in Q4, and is it a one-time cost?
A:The $112 million year-over-year increase in SG&A spending in Q4 was planned and driven by investments in patient access, partnerships (e.g., with the American Heart Association), and field force reinforcement. Some spending was delayed from earlier quarters. The elevated spending is not expected to continue at the same level in 2026, aligning with operating margin guidance of 28%-29%.
Q:What is the expected growth cadence for TAVR and the company overall in 2026?
A:Growth rates are expected to be higher in the first half of 2026 compared to the second half due to tougher year-over-year comparisons and seasonality. Q1 sales growth is expected to be 300 basis points higher on a reported basis due to FX tailwinds. The company remains confident in its 6%-8% growth guidance for TAVR.
Q:What is the potential impact of the TAVR NCD update?
A:The TAVR NCD update is expected to have negligible impact in 2026 but could be significant in 2027 and beyond. The focus is on ensuring timely and equitable access to care, with potential changes to procedural complexity and coverage to label.
Q:What is the market opportunity for LAA and how does Edwards plan to differentiate?
A:The LAA market is still being assessed, but Edwards sees unmet patient needs and plans to enter the market later this year with differentiated technology. The company anticipates a measured commercial rollout and views this as a complementary solution to its existing valvular procedures.
Q:Why was moderate AS not included in the 2026 catalysts, and what is the outlook for this opportunity?
A:Moderate AS was not included because the company is awaiting results from the PROGRESS trial, which will be presented at TCT. While the moderate AS prevalence is larger than severe AS, the company is cautious and awaiting data before making further projections.
Q:What are the implications of lifetime management for TAVR?
A:Lifetime management emphasizes the importance of getting the first procedure right to ensure options for secondary or tertiary procedures. Evidence from studies like EARLY TAVR and PARTNER III supports earlier treatment, which could lead to better clinical and economic outcomes. This is expected to be a key value proposition for the SAPIEN platform.
Q:What is the state of the SAPIEN M3 launch in the U.S. and Europe?
A:The SAPIEN M3 launch is scaling in line with expectations in both the U.S. and Europe. In the U.S., the focus is on centers involved in the ENCIRCLE pivotal study. Early results show high procedural success and great patient outcomes, particularly for patients without other surgical options.
Q:What are the impacts of the European guideline changes for TAVR and mitral/tricuspid therapies?
A:The European guidelines now recommend proactive disease management and reduced the age recommendation for TAVR from 75 to 70. This is expected to drive durable growth as the guidelines are disseminated and implemented. For mitral/tricuspid therapies, the guidelines now classify functional mitral regurgitation as Class I, increasing awareness and referrals.
Q:What is driving the better performance in TAVR in the U.S. recently?
A:The better performance is driven by compelling clinical and economic data, particularly from EARLY TAVR, which has changed the conversation around prioritizing TAVR patients. The success of the SAPIEN 3 Ultra RESILIA platform also contributed significantly.
Q:What caused the Q4 distributor adjustments in SAVR, and will it impact Q1?
A:The Q4 distributor adjustments in SAVR were due to inventory management in China. This is a one-time event and is not expected to impact Q1. The company expects mid-single-digit growth for Surgical in 2026 and beyond.
Q:What is the outlook for moderate AS and the PROGRESS trial?
A:The PROGRESS trial is focused on symptomatic moderate AS patients. While the results are not yet available, the trial enrolled quickly, indicating potential significance. The company is optimistic but will wait for the TCT presentation to provide more insights.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the market size and sales ramp for LAA, stating that the market is still being assessed. Additionally, they did not provide clear data on the mortality rate for untreated moderate AS patients, emphasizing the need to wait for the PROGRESS trial results.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Association
EVOQUE introduction
European
LAAC
PASCAL tricuspid
RD percentage
RESILIA
SAPIEN platform
Sarte
TAVR therapy
TMTT
class evidence
confidence sale
country
durability valve
edge repair
focus SAPIEN
gen PASCAL
guideline
heart valve
introduction gen
launch SAPIEN
leader
patient edge
physician patient
sale rate
scaling EVOQUE
spending
stenosis
strength
summer seasonality
term durability
treatment patient
tricuspid patient
urgency
valve SAPIEN
valve disease
valve initiative
world class
EW Transcript
Edwards Lifesciences Corporation (EW) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Edwards Lifesciences Corporation (EW) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-11
Edwards Lifesciences Corporation (EW) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
Edwards Lifesciences Corporation (EW) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-2
EW Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
